📊 ARWR Key Takeaways
Is Arrowhead Pharmaceuticals, Inc.. (ARWR) a Good Investment?
Arrowhead Pharmaceuticals shows compelling fundamental momentum with extraordinary 23,258% revenue growth indicating successful product commercialization, coupled with a fortress balance sheet (minimal debt, 6.23x liquidity) and positive free cash flow of $93.2M, suggesting the business model is economically viable. While current profitability metrics are severely negative (~-30% margins), this reflects typical early-stage commercialization investment patterns in pharma, and the company has sufficient financial resources and operational cash generation to reach profitability if revenue sustains.
Arrowhead Pharmaceuticals shows a materially improved near-term fundamental profile, with sharp revenue growth, positive operating income, and positive free cash flow alongside a very strong liquidity position and minimal leverage. However, growth quality appears uneven because profitability conversion remains modest relative to the revenue spike, returns on assets and equity are still low, and the reported revenue surge may reflect lumpier biotech economics rather than a fully durable operating trend.
Arrowhead Pharmaceuticals, Inc.. Key Strengths (ARWR)
- Extraordinary revenue growth (23,258% YoY) indicates successful major product launch or commercial milestone
- Positive free cash flow of $93.2M (27.6% FCF margin) despite net losses demonstrates underlying business viability
- Fortress balance sheet with minimal debt ($1.0M), strong equity ($614.0M), and exceptional liquidity (6.23x current ratio) provides runway and financial flexibility
- Strong liquidity with 3.38x current and quick ratios plus over $200M in cash
- Near-zero leverage with only about $1M in long-term debt, limiting balance-sheet risk
- Positive operating income, net income, and free cash flow indicate improved near-term operating performance
ARWR Stock Risks: Arrowhead Pharmaceuticals, Inc.. Investment Risks
- Severe profitability deficit with -29.7% operating margin and -30.2% net margin creates ongoing cash burn at operations level
- Significant disconnect between positive free cash flow and negative net income ($97.9M operating cash flow vs -$101.9M net income) suggests substantial non-cash charges or potential accounting complexity requiring clarification
- Negative returns on capital (ROE -16.6%, ROA -4.5%) indicate poor capital efficiency currently, with execution risk on pipeline programs and profitability timeline
- Revenue growth may be low quality or non-recurring given the extreme YoY spike typical of milestone-driven biotech revenue
- Profitability remains fragile with only 11.7% net margin, 4.3% FCF margin, and 3.2x interest coverage
- Low ROA and ROE suggest the company is not yet generating strong returns from its asset and equity base
Key Metrics to Watch
- Operating margin trajectory and path to profitability over next 2-4 quarters
- Revenue growth sustainability and product adoption rates across commercialized pipeline
- Operating cash flow consistency and reconciliation with net income convergence
- Operating cash flow and free cash flow consistency
- Revenue durability and operating margin sustainability
Arrowhead Pharmaceuticals, Inc.. (ARWR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 27.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 6.23x current ratio provides a solid financial cushion.
ARWR Profit Margin, ROE & Profitability Analysis
ARWR vs Healthcare Sector: How Arrowhead Pharmaceuticals, Inc.. Compares
How Arrowhead Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Arrowhead Pharmaceuticals, Inc.. Stock Overvalued? ARWR Valuation Analysis 2026
Based on fundamental analysis, Arrowhead Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Arrowhead Pharmaceuticals, Inc.. Balance Sheet: ARWR Debt, Cash & Liquidity
ARWR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Arrowhead Pharmaceuticals, Inc..'s revenue has grown significantly by 391% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.92 indicates the company is currently unprofitable.
ARWR Revenue Growth, EPS Growth & YoY Performance
ARWR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $73.7M | -$101.9M | $-0.73 |
| Q1 2026 | $2.5M | $30.8M | $0.22 |
| Q3 2025 | N/A | $22.1M | $0.17 |
| Q2 2025 | N/A | -$125.3M | $-1.02 |
| Q1 2025 | $2.5M | -$132.9M | $-1.24 |
| Q3 2024 | N/A | -$95.6M | $-0.90 |
| Q2 2024 | N/A | $7.4M | $0.07 |
| Q1 2024 | $3.6M | -$41.3M | $-0.39 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Arrowhead Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
ARWR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Arrowhead Pharmaceuticals, Inc.. (CIK: 0000879407)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ARWR
What is the AI rating for ARWR?
Arrowhead Pharmaceuticals, Inc.. (ARWR) has a Combined AI Grade of A from Claude (A) and ChatGPT (B) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ARWR's key strengths?
Claude: Extraordinary revenue growth (23,258% YoY) indicates successful major product launch or commercial milestone. Positive free cash flow of $93.2M (27.6% FCF margin) despite net losses demonstrates underlying business viability. ChatGPT: Strong liquidity with 3.38x current and quick ratios plus over $200M in cash. Near-zero leverage with only about $1M in long-term debt, limiting balance-sheet risk.
What are the risks of investing in ARWR?
Claude: Severe profitability deficit with -29.7% operating margin and -30.2% net margin creates ongoing cash burn at operations level. Significant disconnect between positive free cash flow and negative net income ($97.9M operating cash flow vs -$101.9M net income) suggests substantial non-cash charges or potential accounting complexity requiring clarification. ChatGPT: Revenue growth may be low quality or non-recurring given the extreme YoY spike typical of milestone-driven biotech revenue. Profitability remains fragile with only 11.7% net margin, 4.3% FCF margin, and 3.2x interest coverage.
What is ARWR's revenue and growth?
Arrowhead Pharmaceuticals, Inc.. reported revenue of $337.8M.
Does ARWR pay dividends?
Arrowhead Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find ARWR SEC filings?
Official SEC filings for Arrowhead Pharmaceuticals, Inc.. (CIK: 0000879407) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ARWR's EPS?
Arrowhead Pharmaceuticals, Inc.. has a diluted EPS of $-0.73.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ARWR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Arrowhead Pharmaceuticals, Inc.. has a A grade with 70% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ARWR stock overvalued or undervalued?
Valuation metrics for ARWR: ROE of -16.6% (sector avg: 15%), net margin of -30.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ARWR's AI grade for 2026?
Our dual AI analysis gives Arrowhead Pharmaceuticals, Inc.. a combined A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ARWR's free cash flow?
Arrowhead Pharmaceuticals, Inc..'s operating cash flow is $97.9M, with capital expenditures of $4.7M. FCF margin is 27.6%.
How does ARWR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -30.2% (avg: 12%), ROE -16.6% (avg: 15%), current ratio 6.23 (avg: 2).